AIDS 2016 Podcast

  AIDS 16 Podcast

Podcast Button

About the Program:

Program Overview:

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 21st International AIDS Conference (AIDS 2016). This program consists of three components: (1) CME Internet Symposium: AIDS 2016 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Rapid-Fire Review of AIDS 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (3) From Conference to Clinic: Reviewing and Applying Data From AIDS 2016: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

 

The Rapid-Fire Review of AIDS 2016 features our national faculty panel briefly reviewing the most essential information and data from AIDS 2016. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.

 

All online components of the program can be accessed at www.viraled.com.

 

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AIDS 2016 and it is not sanctioned by the organizers of AIDS 2016.

 

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Use in a clinical setting findings from key new studies on HIV/AIDS diagnosis, management and treatment presented at AIDS 2016
  • Employ the current treatment paradigms for HIV/AIDS, including those supported by studies and data presented at AIDS 2016, to improve patient care
  • Discuss with patients and colleagues the studies and data on newer therapies for HIV/AIDS presented at AIDS 2016 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS

Release Date: July 27, 2016

Expiration Date: July 27, 2017

Estimated time to complete the Podcast: 1 hour, 15 minutes

Media: Internet

Back to Top

Faculty:

 

José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain  

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia, Pennsylvania

Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom

Renslow Sherer, MD
Professor of Medicine,
Section of Infectious Diseases and Global Health,
University of Chicago
Chicago, Illinois


 

Back to Top

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd,Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation:

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr. Jose Arribas, MD:

  • Consulting Fees: ViiV, Janssen, AbbVie, BMS, Gilead

Dr. Ian Frank, MD:

  • Consulting Fees: Gilead
  • Contracted Research: ViiV/GlaxoSmithKline

Dr. Graeme Moyle, MD:

  • Consulting Fees: Tobira Therapeutics, BMS, Gilead, Merck

Dr. Juergen Rockstroh, MD:

  • Consulting Fees: Abbott, AbbVie, BMS, Cipla, Gilead, Janssen, Merck, ViiV
  • Contacted Research: Gilead

Paul Sax, MD:

  • Consulting Fees: AbbVie, BMS, Gilead, Merck, ViiV
  • Contacted Research: Gilead, BMS, ViiV

Renslow Sherer, MD:

  • Consulting Fees: Gilead, Janssen

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, race Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP and Jan Shultz, RN, MSN, CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

Back to Top

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planner. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Back to Top

Instructions for Participation and Credit:

There are no fees for participating and receiving CME credit for this activity. During the period, July 27, 2016 through July 27, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11287. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Back to Top

PIM_small

VE logo 300px 

Supported by an independent educational grant from Gilead Sciences Medical Affairs.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AIDS 2016 and it is not sanctioned by AIDS 2016.


Prepare to print

Share this page:

Get link code to this page                     


Back to Top